Sector News

Shareholder asks Amgen to split into two businesses

October 22, 2014
Life sciences
Amgen is keeping its own counsel after one major investors, hedge fund Third Point, urged the biotech to consider splitting into two separate businesses.
 
High-profile activist investor and Third Point founder Daniel Loeb sent out a letter to backers about Amgen, claiming that the fund is now “one of the company’s largest shareholders”. He wrote that “the obscured fundamental value and investor scepticism that have led to Amgen’s valuation discount can be easily unlocked, saying the biotech needs to focus its R&D efforts and reduce “a bloated cost structure”.
 
Aside from this, however, Mr Loeb is in favour of “a more radical” approach, namely splitting the company in two, one being Amgen’s “assets–cash‐generative mature products and the other an “R&D‐intensive growth products” unit.
 
The letter says Amgen stock could get to $189 a share by the end of 2016 and $218 by the end of 2017 if the company cuts costs and makes R&D more efficient. However, with a split, Third Point believes it could be worth $249 a share in two years; Amgen ended the day up 4.8% after the hedge fund report at $144.09.
 
Board described as ‘open-minded’ by Loeb
 
Mr Loeb was not making an aggressive attack and praised Amgen for taking some steps to cut costs, describing the board as being “open‐minded and receptive to our ideas”. Still, “we firmly believe that the company is at an inflection point,” he wrote, and “we hope to maintain our constructive dialogue with management as the company moves towards closing its valuation gap”.
 
Amgen quickly released a statement “with respect to media inquiries concerning Third Point equity position in Amgen”, saying it has “always appreciated the perspectives of all of its shareholders, including Third Point, and welcomes constructive input toward our common goal of enhancing shareholder value”.
 
The firm added that the board “frequently receives input from shareholders, including ideas like those offered by Third Point” and “continually assess Amgen’s strategic priorities – and, when appropriate, take action”. More on Amgen’s “strategic priorities and update on our restructuring plans” will be laid out “at our business review on October 28”.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”